Drug intelligence / Profile preview

TM2002

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

TM2002 is a novel small-molecule experimental compound synthesized as an inhibitor of advanced glycation end products (AGEs) and oxidative stress. Derived through structure-function analysis of edaravone, TM2002 acts by reducing oxidative stress and inhibiting AGE formation without the blood-pressure-lowering effects characteristic of angiotensin II receptor blockers. Preclinical research has demonstrated its potential in providing renoprotection and cardiovascular protection in diabetic models, as well as neuroprotection in focal cerebral ischemia by reducing infarct volume and inhibiting endoplasmic reticulum (ER) stress.

Other names: TM2002TM-2002TM 20021-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-6-methyl-1,3-dihydro-furo[3,4-c]pyridine-7-ol

Beyond the preview

Go deeper on TM2002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TM2002.

Explore the full profile